Cargando…

Targeting TREM2 for Parkinson’s Disease: Where to Go?

Parkinson’s disease (PD) is one of most common neurodegenerative disorders caused by a combination of environmental and genetic risk factors. Currently, numerous population genetic studies have shown that polymorphisms in myeloid cell-triggered receptor II (TREM2) are associated with a variety of ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiao-xian, Zhang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740229/ https://www.ncbi.nlm.nih.gov/pubmed/35003116 http://dx.doi.org/10.3389/fimmu.2021.795036

Ejemplares similares

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

Human Kinetoplastid Protozoan Infections: Where Are We Going Next?
por: Filardy, Alessandra Almeida, et al.
Publicado: (2018)

The Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer’s Disease
por: Qin, Qi, et al.
Publicado: (2022)

Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
por: Marshall, Michael J. E., et al.
Publicado: (2017)

Venoms as an adjunctive therapy for Parkinson’s disease: where are we now and where are we going?
por: Gazerani, Parisa
Publicado: (2020)

IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?
por: Baeten, Dominique, et al.
Publicado: (2021)

TREM-1 Modulation Strategies for Sepsis
por: Siskind, Sara, et al.
Publicado: (2022)

Endogenous versus exogenous cell replacement for Parkinson’s disease: where are we at and where are we going?
por: Mourtzi, Theodora, et al.
Publicado: (2022)

TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Qiu, Hui, et al.
Publicado: (2021)

TREM2 is associated with tumor immunity and implies poor prognosis in glioma
por: Yu, Mingchen, et al.
Publicado: (2023)

Integrated Analysis Highlights the Immunosuppressive Role of TREM2(+) Macrophages in Hepatocellular Carcinoma
por: Zhou, Lisha, et al.
Publicado: (2022)

Molecular targeted agents—where we are and where we are going
por: Yan, Li
Publicado: (2013)

Function of TREM1 and TREM2 in Liver-Related Diseases
por: Sun, Huifang, et al.
Publicado: (2020)

Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker
por: Cheng, Xin, et al.
Publicado: (2021)

Editorial: Defects in Regulation: How, Where and When the Immune System Can Go Wrong
por: Rijkers, Ger T., et al.
Publicado: (2021)

Soluble TREM2 is a potential biomarker for the severity of primary angiitis of the CNS
por: Guo, Tianshu, et al.
Publicado: (2022)

Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?
por: Mallah, Khalil, et al.
Publicado: (2020)

TMEM59 interacts with TREM2 and modulates TREM2-dependent microglial activities
por: Liu, Zhaoji, et al.
Publicado: (2020)

Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going?
por: Barra, Fabio, et al.
Publicado: (2019)

Targeting therapy in pemphigus: Where are we now and where are we going?
por: Abulikemu, Kailibinuer, et al.
Publicado: (2023)

Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation
por: Li, Hongmu, et al.
Publicado: (2023)

Cognitive Interventions in Parkinson’s Disease: Where We Want to Go within 20 Years
por: Kalbe, Elke, et al.
Publicado: (2018)

Radiation upregulates macrophage TREM-1 expression to exacerbate injury in mice
por: Yamaga, Satoshi, et al.
Publicado: (2023)

The immunoregulatory effect of the TREM2-agonist Sulfavant A in human allogeneic mixed lymphocyte reaction
por: Barra, Giusi, et al.
Publicado: (2023)

The Pathogenesis and Treatment of Cardiovascular Autonomic Dysfunction in Parkinson’s Disease: What We Know and Where to Go
por: Zhu, Shuzhen, et al.
Publicado: (2021)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Where is APC going?
por: Mimori-Kiyosue, Yuko, et al.
Publicado: (2001)

Where are we going?
por: Pawl, Ronald P.
Publicado: (2010)

Where is crystallography going?
por: Grimes, Jonathan M., et al.
Publicado: (2018)

Where is science going?
por: Planck, Max Karl Ernst Ludwig, et al.
Publicado: (1933)

TREM2 in Neurodegenerative Diseases
por: Jay, Taylor R., et al.
Publicado: (2017)

Alzheimer’s Risk Gene TREM2 Determines Functional Properties of New Type of Human iPSC-Derived Microglia
por: Reich, Marvin, et al.
Publicado: (2021)

FKBP Ligands—Where We Are and Where to Go?
por: Kolos, Jürgen M., et al.
Publicado: (2018)

Trem-2 Promotes Emergence of Restorative Macrophages and Endothelial Cells During Recovery From Hepatic Tissue Damage
por: Coelho, Inês, et al.
Publicado: (2021)

Etiopathogenesis of Graves-Basedow disease; where we are and where we are going
por: Nauman, Janusz
Publicado: (2013)

Alzheimer’s disease and infections, where we stand and where we go
por: Monastero, Roberto, et al.
Publicado: (2014)

Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
por: Zhu, Manlian, et al.
Publicado: (2022)

TREM-1, TREM-2 and their association with disease severity in patients with COVID-19
por: Fan, Ruyue, et al.
Publicado: (2023)

Association study of TREM2 polymorphism rs75932628 with leucoaraiosis or Parkinson's disease in the Han Chinese population
por: Li, Zhiming, et al.
Publicado: (2016)

Selenium in the Therapy of Neurological Diseases. Where is it Going?
por: Dominiak, Agnieszka, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_raoooccb7ie2i740lk52rmtlnr